Inactivated canine coronavirus vaccine
AssigneeAmerican Home Products Corporation
InventorsWilliam M. Acree, Bobby Edwards, John W. Black
Life of this patent
Estimating the term…
Abstract
An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
Claims19
A vaccine composition comprising inactivated canine coronavirus having a pre-inactivation titer of at least 10,000 canine coronavirus particles per milliliter and a veterinary pharmaceutically acceptable carrier therefor.
A vaccine composition which comprises an amount of inactivated canine coronavirus strain ATCC VR-2068 sufficient to be effective against canine coronavirus in combination with a carrier suitable for dogs.
A vaccine composition comprising inactivated canine coronavirus present in an amount of about 10,000 to 10,000,000 virus particles per dose as measured by the FAID.sub.50 method, an adjuvant selected from the group consisting of ethylene maleic anhydride and a copolymer of styrene with a mixture of acrylic acid and methacrylic acid, and a non-toxic pharmaceutically acceptable carrier.
A canine coronavirus vaccine composition comprising an amount of inactivated canine coronavirus which is equivalent to a virus titer of from about 4 to 7 logs FAID.sub.50 per milliliter, in an aqueous solution having a pH between about 6.8 and 7.8.
The method of protecting dogs against virulent canine coronavirus comprising inoculating a dog with inactivated canine coronavirus vaccine prepared by a process which comprises the steps of growing a strain of canine coronavirus in a non-oncogenic cell culture and then inactivating the virus.
The method of protecting dogs from meningeal infection due to coronavirus which comprises parenterally inoculating the animal with a killed, adjuvanted coronavirus vaccine.
The process of making a canine coronaviruus vaccine comprising the steps of:
- a. inoculating a suspension of mammalian tissue cell cultures with canine coronavirus;
- b. harvesting said cells after about 24 to 96 hours;
- and
- c. collecting the propagated virus from the harvested cells;
- d. inactivating the propagated virus;
- and
- e. adding an adjuvant to the inactivated composition.
Dependencies are inferred from the claim text.